Gene · 10683
Papers2,335
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,335
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Target-Specific Dermatological Adverse Event Reporting With T-Cell-Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016-2026. | Cancer Med | 2026 | 42670250 | PubTator, text mining | PubMed |
| Pan-cancer analysis of Notch pathway-linked gene expression identifies tumour-specific and sex-stratified prognostic associations. | Clin Transl Radiat Oncol | 2026 | 42668613 | PubTator, text mining | PubMed |
| Advances and future perspectives in the treatment of small cell lung cancer: From chemotherapy and radiotherapy to the era of targeted therapy and immunotherapy. | J Cancer Res Ther | 2026 | 42657984 | PubTator, text mining | PubMed |
| DLL3 expression in neuroendocrine carcinomas: a comparative analysis across tumor origins. | Front Endocrinol (Lausanne) | 2026 | 42656227 | PubTator, text mining | PubMed |
| Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy. | Pharmaceuticals (Basel) | 2026 | 42653714 | PubTator, text mining | PubMed |
| Small Cell Lung Cancer in Transition: Recent Advances in Biology, Treatment, and Precision Medicine. | Cancers (Basel) | 2026 | 42649862 | PubTator, text mining | PubMed |
| Deep molecular profiling of lung neuroendocrine tumours and supra-carcinoids. | Mol Cancer | 2026 | 42649496 | PubTator, text mining | PubMed |
| Atezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature. | Semin Oncol | 2026 | 42641427 | PubTator, text mining | PubMed |
| Clinical utility of molecular profiling in rare lung neuroendocrine neoplasms. | Front Oncol | 2026 | 42639261 | PubTator, text mining | PubMed |
| Screening of potential antibody-drug conjugate (ADC) targets in neuroendocrine carcinoma of the cervix: implications for targeted therapy. | J Gynecol Oncol | 2026 | 42625475 | PubTator, text mining | PubMed |
| Proteomic Profiling Identifies CLDN3 as a Tumor-Selective Therapeutic Target in Small Cell Lung Cancer. | bioRxiv | 2026 | 42619739 | PubTator, text mining | PubMed |
| Update 2026: Management of Small Cell Lung Cancer. | Lung | 2026 | 42618851 | PubTator, text mining | PubMed |
| Systemic Therapy for High-Grade Olfactory Neuroblastoma: From Molecular Lineages to Targeted and Immune Strategies. | Cancer Manag Res | 2026 | 42614802 | PubTator, text mining | PubMed |
| DLL3 serves as a pivotal hub bridging malignant progression and immunosuppression in NECC with therapeutic implications validated via the organoid-TIL co-culture system. | Genes Dis | 2026 | 42602894 | PubTator, text mining | PubMed |
| How Often are druggable mutations detectable in Metastatic Castration Resistant Prostate Cancer? | Urol Int | 2026 | 42594033 | PubTator, text mining | PubMed |
| Multiplexed quantitative proteomics in small-cell lung cancer: stage-linked DLL3 distribution and an independent prognostic signal of thymidine phosphorylase. | Transl Lung Cancer Res | 2026 | 42582771 | PubTator, text mining | PubMed |
| DLL3-directed immune redirection in small-cell lung cancer: a lineage-defined vulnerability that doubles as an escape route. | Front Immunol | 2026 | 42582332 | PubTator, text mining | PubMed |
| Enzalutamide promotes an early plasticity-associated transcriptional state without terminal neuroendocrine differentiation in prostate cancer cells. | Front Oncol | 2026 | 42568401 | PubTator, text mining | PubMed |
| Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid. | J Thorac Oncol | 2026 | 42562260 | PubTator, text mining | PubMed |
| How diverse therapeutic strategies reshape the tumor immune microenvironment in small cell lung cancer: from radiation to engineered immunotherapies. | Biochem Pharmacol | 2026 | 42556480 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10683/papers?page=2